

FOR IMMEDIATE RELEASE

PCI Pharma Services announces expansion of Cold Chain capacity at Philadelphia site

Philadelphia Center of Excellence adds 60% capacity increase for onsite Cold Chain storage.

Philadelphia, PA – September 05, 2017 – Leading pharmaceutical outsourcing services provider PCI Pharma Services (PCI) has announced the investment in a considerable expansion of its onsite Cold Chain storage at its Philadelphia site. PCI announced an additional 500 pallet spaces have been added, increasing its onsite 2-8°C refrigerated storage at its commercial packaging center of excellence to more than 1,300 pallets. The 450,000 square foot site features contract packaging services for Over-the-Counter medicines, Ethical pharmaceuticals, Medical Devices, as well as Animal Health therapies. The Cold Chain expansion is slated to support PCI's growing presence in Biotech medicines.

"It has been estimated Biologics represent more than 37% of all drugs in pipeline development," states Ken Richardson, PCI Vice President of Global Engineering. "That certainly mirrors the trends we are seeing towards growth in parenteral delivery forms and medicines requiring strict end-to-end Cold Chain logistics. On average, we launch over 50 products a year and a large proportion of those are drugs with needs for end-to-end Cold Chain. We continue to invest considerably in both areas – adding infrastructure to meet growing demand for vial labeling, syringe labeling and assembly, as well as labeling and assembly of autoinjectors and pens, complemented by investing in ample site storage for these medicines needing refrigerated or frozen conditions. We anticipate these needs will increase considerably as these pipeline medicines reach commercialization, in addition to anticipated growth associated with development of biosimilars. PCI is well positioned to support clients in both areas."

PCI's investment in Cold Chain infrastructure and parenterals packaging at the Philadelphia site continues a series of investments in this fast-growing market segment. PCI's European based Hay-on-Wye facility recently announced the installation of a state-of-the-art multipurpose custom engineered parenteral labeling unit manufactured by Marchesini capable of supporting a variety of injectable delivery forms such as vials, syringes, and autoinjectors. PCI's Rockford, Illinois site also recently announced installation of cryogenic storage in support of the growing cell and gene therapy market, another market segment requiring strict temperature controlled activities that often range from -140°C to -196°C. PCI features multiple sites across its global supply network with strictly monitored controlled temperature conditions to meet exacting client requirements, ranging from +25°C down to -196°C.

About PCI

The global healthcare industry trusts PCI for the drug development solutions that increase their products' speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over four decades in the healthcare business. Leading technology and continued investment enables us to address global development needs throughout the product life cycle — from Phase I clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner,

with the shared goal of improving patients' lives. For more information, please visit www.pciservices.com or follow us on Twitter at [@PCI_Social](https://twitter.com/PCISocial).

Contact

Chantel Richman / Carrie Lowe at Remarkable Content

chantel.richman@remarkablegroup.co.uk / carrie.lowe@remarkablegroup.co.uk

T: +44 (0) 1962 893 853 / 913